thyroid cancer and glp-1 Glucagon-like peptide 1 receptor agonist use risk of cancer: Scandinavian cohort study Do GLP-1s cause thyroid cancer?

As healthcare evolves in 2025, Cardinal Healths impact is more significant than ever

Novo Nordisk reined in its growth forecasts for the year in its second-quarter financial results update, blaming "persistent use of compounded GLP-1s, slower-than-expected market expansion, and competition." Compounding of semaglutide should have come to a halt in the US since the drug was removed from the FDA list of medicines in short supply, but various companies continue to provide compounded GLP-1s under a loophole that allows the sale of 'personalised' formulations

, de Lucena, D

[1] [3] Some medications, such as chloramphenicol, may interact with B12 therapy